The human interleukin IL-6 was originally cloned in 1986. In 1993, William Ershler, in his article "IK-6: A Cytokine for Gerontologists," indicated IL-6 as one of the main signaling pathways modulating the complex relationship between aging and chronic morbidity. Over the last 12 years, our understanding of the role of IL-6 in human physiology and pathology has substantially grown, although some of the questions originally posed by Ershler are still debated. In this review, we will focus on IL-6 structure, IL-6 signaling, and trans signaling pathways, and the role of IL-6 in geriatric syndromes and chronic disease. In the final section of this review, we dissect the critical elements of the IL-6 signaling pathway and point out targets for intervention that are targeted by emerging drugs, some still on the horizon and others already being tested in clinical trials.
|Original language||English (US)|
|Number of pages||10|
|Journal||Journals of Gerontology - Series A Biological Sciences and Medical Sciences|
|State||Published - Jun 2006|
ASJC Scopus subject areas